Insider Buying: IRIDEX (NASDAQ:IRIX) Major Shareholder Acquires $23,000.00 in Stock

Posted by Geri Gentry on Oct 10th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin purchased 20,000 shares of the stock in a transaction on Thursday, May 8th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $23,000.00. Following the transaction, the insider directly owned 197,497 shares in the company, valued at approximately $227,121.55. The trade was a 11.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Price Performance

Shares of IRIX stock opened at $0.89 on Friday. IRIDEX Corporation has a one year low of $0.61 and a one year high of $1.65. The stock has a market cap of $15.64 million, a P/E ratio of -4.45 and a beta of 0.67. The company has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $0.95.

IRIDEX (NASDAQ:IRIX – Get Free Report) last released its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. As a group, equities research analysts anticipate that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Institutional Trading of IRIDEX

Several institutional investors have recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC acquired a new position in IRIDEX in the 2nd quarter valued at $41,000. Weber Capital Management LLC ADV acquired a new stake in shares of IRIDEX during the second quarter worth $206,616. Diversify Advisory Services LLC bought a new stake in shares of IRIDEX in the second quarter valued at about $30,000. Bank of New York Mellon Corp bought a new stake in shares of IRIDEX in the second quarter valued at about $29,000. Finally, Renaissance Technologies LLC grew its stake in shares of IRIDEX by 6.7% in the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after acquiring an additional 25,067 shares in the last quarter. 20.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.00.

Read Our Latest Stock Report on IRIDEX

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.